Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 07, 2018 17:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Conference

NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
May 08, 2018 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update

Worldwide Ocaliva net sales of $35.2 million in the first quarter of 20182018 worldwide Ocaliva net sales currently expected to be between $170 million and $185 millionContinuing to advance leading...
May 01, 2018 17:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
April 24, 2018 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors

NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
April 13, 2018 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel...
April 05, 2018 08:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock

NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
April 04, 2018 16:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Proposed $120 Million Public Offering and Concurrent $92 Million Private Placement of Common Stock

NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
March 26, 2018 16:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Conference

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
March 23, 2018 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018

NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel...
March 13, 2018 17:48 ET | Source: Intercept Pharmaceuticals, Inc.

CORRECTING and REPLACING -- Intercept to Present at Upcoming Conference

NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) please note that the conference date should be...